{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000187","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.702166+00:00","generated_at":"2026-06-30T07:35:32.894259+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy","bullets":["KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.","Invention pertains to generating IL-17 antitumor effector cells by inhibiting NR2F6.","NR2F6 described as an immune checkpoint and cancer stem cell differentiator."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000187","json":"https://secwatch.observer/filing/0001607062-21-000187.json","markdown":"https://secwatch.observer/filing/0001607062-21-000187.md","text":"https://secwatch.observer/filing/0001607062-21-000187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/0001607062-21-000187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/rgbp070221form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T07:35:32.894259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}